Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Pentoxifylline
Bronchodilator · Rheologic agent
BronchodilatorRheologic agent
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
3 major
SEVERE in our sources
PREGNANCY
Avoid—toxicity in animal studies.
FDA category + note
Top interactions
- AcalabrutinibSevereDatabaseDDInter
- InotersenSevereDatabaseDDInter
- KetorolacSevereDatabaseDDInter
Mechanism
Pentoxifylline is a methylxanthine derivative that is called a rheologic modifier for its effects on increasing the deformability of red blood cells.
Dosing
- Adult
- l INDICATIONS AND DOSE Intermittent claudication in patients without rest pain and no peripheral tissue necrosis ▶ BY MOUTH Adult: 100 mg twice daily, to be taken 30 minutes before food, cilostazol should be initiated by those experienced in the management of intermittent claudication, patients receiving cilostazol should be assessed for improvement after 3 months; consider discontinuation of trea…
Pregnancy & lactation
Pregnancy
Avoid—toxicity in animal studies.
Drug interactions
Inotersen
Severe
Database
Clinical effect not specified
Source: DDInter
Ketorolac
Severe
Database
Clinical effect not specified
Source: DDInter
9 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Bronchodilator drugs
Ask House about Pentoxifylline
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team